CR20130059A - Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico - Google Patents

Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico

Info

Publication number
CR20130059A
CR20130059A CR20130059A CR20130059A CR20130059A CR 20130059 A CR20130059 A CR 20130059A CR 20130059 A CR20130059 A CR 20130059A CR 20130059 A CR20130059 A CR 20130059A CR 20130059 A CR20130059 A CR 20130059A
Authority
CR
Costa Rica
Prior art keywords
acid derivatives
procedure
diaminopropionic acid
enantiomeric forms
prepare
Prior art date
Application number
CR20130059A
Other languages
English (en)
Inventor
Claus-Dieter Graf
Joerg Rieke-Zapp
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130059(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20130059A publication Critical patent/CR20130059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invención se refiere a un procedimiento para preparar lasformas enantioméricas de derivados de ácido 2,3-diaminopropiónico de fórmula (I), en donde R1, R2 y R3 están definidos como en las reivindicaciones, por resolución de racemato.
CR20130059A 2010-08-12 2013-02-11 Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico CR20130059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12
US201161428336P 2011-12-30 2011-12-30

Publications (1)

Publication Number Publication Date
CR20130059A true CR20130059A (es) 2013-03-25

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130059A CR20130059A (es) 2010-08-12 2013-02-11 Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico

Country Status (24)

Country Link
US (2) US8877926B2 (es)
EP (1) EP2603491B1 (es)
JP (1) JP6000248B2 (es)
KR (1) KR20130099044A (es)
CN (1) CN103209961A (es)
AR (1) AR082621A1 (es)
AU (1) AU2011288533A1 (es)
BR (1) BR112013002985A2 (es)
CA (1) CA2807979A1 (es)
CL (1) CL2013000420A1 (es)
CO (1) CO6690757A2 (es)
CR (1) CR20130059A (es)
DO (1) DOP2013000035A (es)
EC (1) ECSP13012434A (es)
GT (1) GT201300038A (es)
MA (1) MA34464B1 (es)
MX (1) MX2013001647A (es)
PE (1) PE20131326A1 (es)
PH (1) PH12013500256A1 (es)
RU (1) RU2013110525A (es)
SG (1) SG187791A1 (es)
TW (1) TW201221504A (es)
UY (1) UY33552A (es)
WO (1) WO2012019967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2787998T (lt) 2011-12-06 2017-02-10 Sanofi 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-karboksirūgšties [(s)-1-karbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amido kristalinės formos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
ECSP13012434A (es) 2013-03-28
EP2603491A1 (en) 2013-06-19
JP6000248B2 (ja) 2016-09-28
SG187791A1 (en) 2013-03-28
WO2012019967A1 (en) 2012-02-16
JP2013533296A (ja) 2013-08-22
US20150018554A1 (en) 2015-01-15
BR112013002985A2 (pt) 2017-11-07
MX2013001647A (es) 2013-03-21
AR082621A1 (es) 2012-12-19
CA2807979A1 (en) 2012-02-16
AU2011288533A1 (en) 2013-02-28
GT201300038A (es) 2015-06-24
EP2603491B1 (en) 2014-09-24
MA34464B1 (fr) 2013-08-01
CL2013000420A1 (es) 2013-04-05
US9434696B2 (en) 2016-09-06
RU2013110525A (ru) 2014-09-20
US20130211085A1 (en) 2013-08-15
PE20131326A1 (es) 2013-11-12
TW201221504A (en) 2012-06-01
UY33552A (es) 2012-03-30
DOP2013000035A (es) 2013-03-15
US8877926B2 (en) 2014-11-04
CN103209961A (zh) 2013-07-17
CO6690757A2 (es) 2013-06-17
PH12013500256A1 (en) 2013-03-18
KR20130099044A (ko) 2013-09-05

Similar Documents

Publication Publication Date Title
JOP20210065B1 (ar) andnbsp;andnbsp;andnbsp;5-فلورو-H1 بيرازولوبيريدينات مستبدلة andnbsp;في شكل متبلور
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
UY34006A (es) Imidazopiridazinas
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
UY36735A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20150370A (es) Compuestos antivirales
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
MX2019003738A (es) Compuestos antivirales.
ECSP13012612A (es) Derivados de quinazolin-4-(3h)-ona utilizados como inhibidores de p13 cinasa
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
CR20140275A (es) Triazolopiridinas sustituidas
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
BR112013019520A2 (pt) método para produção de 2,3-butanodiol por fermentação
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
ECSP099070A (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
BR112012030412A2 (pt) ésteres de dialcanolamina quaternários
BR112013011417A2 (pt) microrganismos para a produção de 1,3-propanodiol usando alta concentração de glicerina
BR112012019866A8 (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
DOP2015000007A (es) Métodos para preparar triazolopiridinas sutituidas
MX2013007726A (es) Derivados de 2-metoxi-piridin-4-ilo.
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.